Biogen (BIIB) PT Raised to $369 at Morgan Stanley
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $199.71 +1.59%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Join SI Premium – FREE
Morgan Stanley raised its price target on Biogen (NASDAQ: BIIB) to $369.00 (from $365.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- Robinhood Markets (HOOD) PT Raised to $130 at Cantor Fitzgerald
- Alkami Technology Inc (ALKT) PT Lowered to $19 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
